Insilico Medicine revealed that the first drug developed by artificial intelligence, known as INS018_055, has entered Phase 2 of clinical trials. The drug is aimed at treating idiopathic pulmonary fibrosis (IPF), a rare progressive lung disease. The CEO of Insilico Medicine, Alex Zhavoronkov, stated that the drug is being tested just like any other traditional drug, in terms of safety and effectiveness. However, the process of discovery and design is much newer and has been accelerated through the use of AI. Zhavoronkov explained the four steps involved in developing a new drug: finding a biological mechanism driving the disease, creating a drug that targets the mechanism, conducting studies in animals and humans, and obtaining approval from regulatory agencies for use as a treatment. In the traditional process, targets are found by analyzing scientific literature and databases for links to diseases. On the other hand, AI allows scientists to analyze large amounts of data, identify connections, and create new drug molecules. Insilico Medicine used AI to discover a new target for IPF and generate a molecule to act on that target. The chosen molecule, INS018_055, is currently being tested in Phase 2 clinical trials. The current treatments for IPF, such as pirfenidone and nintedanib, only provide limited relief and come with unpleasant side effects. Insilico Medicine hopes that INS018_055 will offer better outcomes for patients. The data from the ongoing clinical trials will determine the drug’s safety and effectiveness. If successful, the drug will move on to larger trials before obtaining approval from the FDA. Although recruiting patients for rare diseases like IPF is challenging, the research team is optimistic that the drug will be available for patients in the near future.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
